Continuous treatment with the androgen receptor inhibitor enzalutamide (Xtandi) in combination with docetaxel significantly improved progression-free survival (PFS) compared with placebo plus docetaxel in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed while receiving enzalutamide alone in the phase 3b PRESIDE clinical trial. Axel S. Merseburger, MD, PhD, Chairman, Clinic of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany, reported the results at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium.
The investigators hypothesized that continuous treatment with enzalutamide may help maintain control of responsive tumor lesions and may allow the addition of docetaxel to target pathways that enhance tumor growth.
Study Details
The double-blind, open-label, randomized PRESIDE study enrolled 687 patients in period 1, when open-label enzalutamide was given. Patients who had no prostate-specific antigen (PSA) response or had no evidence of radiographic progression were not eligible for period 2, during which 273 patients remained and were randomized in a 1:1 ratio to enzalutamide 160 mg daily, or to placebo. All patients also received docetaxel 75 mg/m2 every 3 weeks, and prednisone 10 mg daily. Treatment continued until disease progression.
The median patient ages were 71.5 years and 69 years for the enzalutamide and placebo arms, respectively. The median baseline PSA levels were 36.9 ng/mL and 28.1 ng/mL, respectively, and 55.9% versus 57% of the patients had a Gleason score of ≥8, respectively. Bone lesions were present in 41.9% of the patients in the enzalutamide arm and in 34.8% of the placebo arm, soft tissue metastases in 21.3% and 17.8%, respectively, and lesions at both sites were present in 36.8% and 47.4%, respectively.
The median PFS was 9.53 months with enzalutamide plus docetaxel versus 8.28 months with placebo plus docetaxel (hazard ratio, 0.72; P = .027). In addition, enzalutamide treatment delayed the time to PSA progression (8.4 months vs 6.2 months with placebo arm).
The PFS by subgroup analysis was consistent with results from the overall study population. No significant difference in PFS was observed between the patients with a baseline Eastern Cooperative Oncology Group performance status of 0 and 1. The PFS was also similar by disease location in bone only, tissue only, and in both locations (P = .0097).
The PSA level decreased by 37.12% from baseline to week 13 in the enzalutamide arm compared with 9.11% in the placebo arm. The objective response rate based on RECIST version 1.1 was 31.6% in the enzalutamide arm and 25.9% in the placebo arm, with complete response rates of 19.1% and 12.6%, respectively.
“These data suggest that continued treatment with enzalutamide plus docetaxel offers a clinical benefit and could be a future treatment option for some patients who progress on enzalutamide alone,” said Dr Merseburger.
The safety profile of enzalutamide was consistent with its known profile. Serious treatment-emergent adverse events were observed in 49.3% of patients who received enzalutamide versus 38.5% of the patients who received placebo. Adverse events leading to discontinuation occurred in 8.8% and 6.7% of the patients, respectively, and 9.6% and 5.2% of the patients, respectively, died from any cause.
Expert Commentary
According to Elisabeth I. Heath, MD, FRCP, Associate Director, Translational Science, and Professor, Hematology-Oncology, Karmanos Cancer Institute, Hudson-Webber Cancer Research Center, Detroit, MI, patients to consider for continuous enzalutamide combination therapy, based on the results from PRESIDE, are those whose disease responds initially to treatment with enzalutamide, but who ultimately have disease progression within 15 months; those with ongoing clinical benefit from enzalutamide; and those who demonstrate fitness for combination therapy.
“The addition of docetaxel in men who are progressing on enzalutamide is a treatment option due to an increase in PFS in men with mCRPC,” Dr Heath said.
